Background
==========

Considerable attention to the safe use of Chinese herbal medicines has been drawn since the reports of nephropathy due to some Chinese herbs \[[@B1],[@B2]\]. The reported nephrotoxicity and carcinogenicity of aristolochic acid (AA) was subsequently corroborated by clinical reports \[[@B3]-[@B9]\], results from animal models \[[@B10]-[@B12]\] and the detection of AA bound DNA adducts in kidney and ureteral tissues \[[@B13]-[@B16]\]. These reports led to the prohibition of all AA-containing products in many countries and regions, such as the USA, UK, Canada, Germany, Australia and Taiwan \[[@B13],[@B17]-[@B20]\]. The Bureau of Food and Drug Analysis in Taiwan is mandated to regularly monitor AA-containing Chinese herbal products (AA-CHPs) in the market by quantitative and qualitative analysis.

Substitution of specific AA-containing herbs has been reported. *Caulis Akebiae*(*Mutong*), *Radix Stephaniae Tetrandrae*(*Fangji*) and *Radix Aucklandiae*(*Muxiang*) may potentially be substituted by *Caulis Aristolochiae Manshuriensis*(*Guanmutong*) \[[@B21]\], *Radix Aristolochiae Fangchi*(*Guanfangji*) \[[@B22]-[@B24]\] and *Radix Aristolochiae*(*Qingmuxiang*) respectively. Inappropriate uses were reported after the ban had been imposed \[[@B18],[@B25]-[@B28]\]. Containing trace amounts of AA \[[@B29],[@B30]\], *Radix et Rhizoma Asari*(*Xixin*) is banned \[[@B19],[@B31]\] but still available in Mainland China, Taiwan, Japan and Korea \[[@B32]\].

The CHPs currently covered by the National Health Insurance (NHI) of Taiwan do not include raw herbs. Manufactured and marketed as extract products, CHPs are equivalent to the \'finished herbal products\' or \'mixed herbal products\' as defined by the World Health Organization (WHO) \[[@B33]\]. In terms of safety, AA-CHPs may be quite different from individual AA herbs because traditional Chinese medicine formulae that are used to make AA-CHPs were designed to not only enhance the efficacy of the herbs but also reduce their toxicity \[[@B34],[@B35]\].

This study aims to determine the prescription profile of AA-CHPs in Taiwan based on data for the period between January 1997 and November 2003. The prescription data for 2004 enable us to determine whether the ban on the use of AA herbs was complied with in Taiwan \[[@B36]\] where the high incidence and prevalence rates of chronic kidney disease were associated with the use of herbal medicines \[[@B37]\].

Methods
=======

Selection of herbs
------------------

AA-CHPs in this study are defined as the Chinese herbal products that are (1) either suspected of containing AAs (AA herbs), e.g. *Herba Aristolochiae*(*Tianxianteng*), *Fructus Aristolochiae (Madouling)*and *Xixin*, or (2) likely to be adulterated by AA herbs, e.g. *Fangji*, *Muxiang*and *Mutong*. In Taiwan, the ban on some SAA herbs, including *Guanfangji*, *Qingmuxiang*, *Guanmutong*, *Madouling*, and *Tianxianteng*, took effect on 4 November 2003. However *Xixin*, *Mutong*, *Fangji*and *Muxiang*, may still be used if correct species without adulteration or malnomenclature are assured. We therefore examined all the CHPs licensed by the Committee on Chinese Medicine and Pharmacy (CCMP) between 1997 and 2003, including single herbs and herbal formulae, to determine whether they include AA herbs. The inclusion period runs from the start of the research database (1 January 1997) to one day prior to the ban on AA-CHPs (3 November 2003). The databases used in this study were also used in similar studies \[[@B38],[@B39]\].

List of licensed Chinese herbal products
----------------------------------------

The CCMP list shows that 18,019 CHPs were licensed during the study period, of which 9,837 were covered by the NHI. CHPs in Taiwan can only be prescribed by Chinese medicine practitioners and CHP prescriptions usually contain more than one single herb/herbal formula \[[@B38]\]. For simplicity, all CHPs with the same CCMP standard formulae are classified under the same categories, regardless of slight variations among products of different pharmaceutical companies \[[@B40]\]. For example, there are 46 approved licenses for the formula *Duhuo Jisheng Tang*.

National Health Insurance reimbursement database
------------------------------------------------

The NHI covers over 96.16% of the population in Taiwan \[[@B41]\]. Our cohort of 200,000 patients was randomly selected from all NHI beneficiaries, according to the methods of Knuth \[[@B42]\] and Park and Miller \[[@B43]\] using random numbers generated by a program written in Sun WorkShop C 5.0. Under secure encryption, all reimbursement data of the cohort from 1996 onwards were collected and analyzed. The database contains all transactions of health care services for the cohort, including both Western medicine and Chinese medicine, with the dates and some details of all outpatient visits, hospitalization, diagnoses, prescribed CHPs (dosages, dosage frequency and prescription duration) and the personal data of the patients. The database was made available by the National Health Research Institutes in 2002 and was widely used by researchers in various fields \[[@B44]\]. The main datasets used were \'Ambulatory care expenditure by visits\', \'Details of ambulatory care orders\' and \'Registry for contracted medical facilities\'. As the NHI of Taiwan does not cover the use of Chinese medicine in inpatient services, we only studied the use of Chinese medicine in outpatient services. Using the data of 2004, we also studied whether Chinese medicine practitioners complied with the ban on AA herbs.

Statistical analysis
--------------------

Data analysis was undertaken by descriptive statistics, including the decomposition of the AA herb contents of the licensed and prescribed AA-CHP items, AA-CHP prescription rates stratified by patient\'s gender and age, the median (plus 5 and 95 percentiles) of cumulated doses of AA herbs, the population distribution of those who had been potentially exposed to AA herbs at various dosages, the frequencies of the disease categories prescribed with AA-CHPs, the most frequently prescribed herbal formulae potentially containing AA herbs, and the most common duration and dosage frequencies of AA-CHP prescriptions. All of the above analyses were performed using the SAS software package (version 9.1, USA).

Results
=======

Between 1 January 1997 and 3 November 2003, 1,218 (12.38%) AA-CHPs were identified out of the total of 9,837 licensed CHPs, of which the most frequently prescribed were *Muxiang*(35.3%) and *Xixin*(30.7%). A total of 526,867 cases of prescribed and reimbursed AA-CHPs were recorded (Table [1](#T1){ref-type="table"}). Among all the AA-CHPs, *Xixin*was the most frequently prescribed (44.7%). The co-existence of more than two AA herbs was identified in both licensed and prescribed AA-CHPs, of which *Mutong*and *Xixin*were the most frequently seen. During the study period, 105,737 patients (52.9%) sought Chinese medicine treatment on at least one occasion, of which 78,644 were prescribed with AA-CHPs. The AA-exposed population demonstrated the prevalence of middle-aged female patients (Table [2](#T2){ref-type="table"}). More than 70% of the patients were exposed to lower cumulated doses (less than 30 mg) of all AA herbs in CHPs; about 7% of the patients were prescribed with *Xixin*, *Mutong*and *Madouling*at cumulated doses of over 100 g (Table [3](#T3){ref-type="table"}). Given that the random sample of this cohort accounts for approximately 1% of the population of Taiwan, it may be inferred that about 344,300 people were exposed to such high cumulated doses of *Xixin*, while about 234,700 people were exposed to similarly high cumulated doses of *Mutong*.

###### 

Distribution frequencies of licensed and prescribed Chinese herbal products potentially containing aristolochic acid, 1997--2003\*

                                              Licensed CHPs   Prescribed CHPs             
  ------------------------------------------- --------------- ----------------- --------- -------
  Types of AA herbs included                                                              
   *Tianxianteng*                             1               0.1               339       0.1
   *Madouling*                                18              1.5               1,395     0.3
   *Xixin*                                    307             25.2              191,297   36.3
  Herbs potentially adulterated by AA herbs                                               
   *Fangji*(by *Guanfangji*)                  174             14.3              93,447    17.7
   *Muxiang*(by *Qingmuxiang*)                409             33.6              107,014   20.3
   *Mutong*(by *Guanmutong*)                  225             18.5              87,073    16.5
  ≥2 of above herbs                                                                       
   *Mutong*and *Muxiang*                      17              1.4               2,200     0.4
   *Mutong*and *Xixin*                        63              5.2               44,101    8.4
   *Muxiang*and *Xixin*                       2               0.2               \-        \-
   *Muxiang*, *Xixin*and *Tianxianteng*       2               0.2               1         \-
  Total                                       1,218           100.0             526,867   100.0

\*The table shows the distribution frequencies of licensed and prescribed Chinese herbal products (CHPs) that may potentially contain aristolochic acid (AA).

###### 

Prescription frequencies of Chinese herbal products (by gender, age and types of herbs), 1997--2003\*

  Herbal products                             Gender   Age (years)                                    
  ------------------------------------------- -------- ------------- ------ ----- ------ ------ ----- -----
  Any CHPs                                    35.4     41.8          11.1   7.3   23.6   26.5   7.2   1.6
  AA-CHPs                                     25.9     31.6          6.8    5.8   17.6   20.6   5.6   1.2
  Types of AA herbs included                                                                          
  *Xixin*                                     14.8     20.2          4.9    3.1   9.8    12.7   3.7   0.8
  *Madouling*                                 0.2      0.3           0.1    \--   0.1    0.2    0.1   \--
  *Tianxianteng*                              \--      \--           \--    \--   \--    \--    \--   \--
  Herbs potentially adulterated by AA herbs                                                           
  *Fangji*                                    11.5     13.6          0.8    2.1   7.6    11.0   3.0   0.6
  *Muxiang*                                   10.3     14.7          2.7    2.5   7.9    9.2    2.2   0.5
  *Mutong*                                    10.8     14.4          3.3    2.4   7.6    9.2    2.2   0.4

\*The prescription frequencies (per 1,000 person-years) of Chinese herbal products (CHPs) are stratified by gender, age and the types of AA containing herbs (AA herbs) or those potentially adulterated by AA herbs.

###### 

Distribution frequencies\* of Chinese herbal product prescriptions potentially containing aristolochic acid (by cumulated doses), 1997--2003

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Herbal product                              Cumulated dose (g)\   No. of patients   Percentages (%) of patients with various cumulated doses of AA herbs                             
                                              Median (90% CI^\#^)                                                                                                                      
  ------------------------------------------- --------------------- ----------------- ---------------------------------------------------------------------- ------ ------ ----- ----- -----
  Types of AA herbs included                                                                                                                                                           

  *Xixin*                                     12.6 (1.5--128.5)     47,869            54.1                                                                   18.6   13.6   6.4   3.3   4.0

  *Tianxianteng*                              10.5 (0.03--87.0)     110               66.0                                                                   19.4   2.9    7.8   1.9   1.9

  *Madouling*                                 21.0 (4.0--120.0)     665               36.0                                                                   29.1   19.7   7.5   4.3   3.4

  Herbs potentially adulterated by AA herbs                                                                                                                                            

  *Fangji*                                    6.0 (1.1--50.8)       34,462            77.8                                                                   12.0   6.2    2.2   0.9   1.0

  *Muxiang*                                   8.0 (1.2--70.0)       34,195            69.1                                                                   15.9   8.8    3.2   1.6   1.5

  *Mutong*                                    14.0 (1.8--124.4)     34,399            51.8                                                                   19.9   14.6   6.7   3.2   3.8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Distribution frequency refers to the number of patients who have been prescribed with Chinese herbal products that may potentially contain aristolochic acid (AA).

^\#^90% CI: 90% confidence interval

The major disease categories often prescribed with AA-CHPs include respiratory diseases (132,598 visits) and musculoskeletal/connective diseases (77,153 visits), followed by symptoms/signs/ill-defined conditions (68,466 visits), digestive diseases (46,646 visits) and injury/poisoning (40,260 visits). Among all AA-CHPs, 90.7% were in the form of herbal formulae, of which the most frequently prescribed were *Shujing Huoxie Tang*(containing *Fangji*), *Chuanqiong Chadiao San*(containing *Xixin*) and *Longdan Xiegan Tang*(containing *Mutong*) (Table [4](#T4){ref-type="table"}).

###### 

Distribution frequencies\* of the most commonly prescribed herbal formulae potentially containing aristolochic acid, 1997--2003

  Herbal formula containing AA herbs   Prescription frequency   Type of AA herbs included or potentially adulterated   
  ------------------------------------ ------------------------ ------------------------------------------------------ -----------
  *Shujing Huoxie Tang*                75,472                   14.3                                                   *Fangji*
  *Chuanqiong Chadiao San*             58,004                   11.0                                                   *Xixin*
  *Longdan Xiegan Tang*                42,351                   8.0                                                    *Mutong*
  *Xiaoqinglong Tang*                  42,241                   8.0                                                    *Xixin*
  *Duhuo Jisheng Tang*                 41,594                   7.9                                                    *Xixin*
  *Xinyi San*                          39,323                   7.5                                                    *Mutong*
  *Xiangsha Liujunzi Tang*             23,580                   4.5                                                    *Muxiang*
  *Guipi Tang*                         16,946                   3.2                                                    *Muxiang*
  *Xiaofeng San*                       16,186                   3.1                                                    *Mutong*
  *Zhenggu Zijin Dan*                  15,105                   2.9                                                    *Muxiang*
  Total                                526,867                  100.0                                                  

\*Distribution frequency refers to the top ten most commonly prescribed herbal formulae that may potentially contain aristolochic acid.

About 97.5% of all AA-CHPs were prescribed for treatment of no more than seven days and the most common dosage frequency (82.7%) was three times a day. Furthermore, our investigation of the 2004 database found an alarming number of cases of CHPs containing AA herbs (*Tianxianteng*or *Madouling*) prescribed after the ban was announced on 4 November 2003. We found a total of 68 records involving the prescription of these herbs to 25 patients by 19 Chinese medicine practitioners (in 19 clinics). Therefore, our estimate was that about 2,760 patients (= 25\*23,000,000\* 96.16%/200,000) were prescribed with the prohibited AA-CHPs at least once during the study period.

Discussion
==========

This study demonstrated that more than one-third (39.3%) of the population in Taiwan were prescribed with AA-CHPs during the study period and that the cumulated doses of AA-CHPs for each patient may have exceeded 100 g (Table [3](#T3){ref-type="table"}). Exposure to *Xixin*and *Mutong*was the most extensive. Therefore, it is necessary to monitor the use of CHPs. Special attention should be drawn to prescriptions for patients suffering from respiratory and/or musculoskeletal diseases and to the herbal formulae with AA herbs (Table [4](#T4){ref-type="table"}).

There are a few major limitations to this study. Firstly, the study was based upon the NHI reimbursement data. Specific information is not available for causal studies or inference. Secondly, different pharmaceutical companies may obtain their herbs from different sources which may have different degrees of AA herb adulterations. The estimation of cumulated AA doses may be inaccurate. Thirdly, this study did cover the consumption of medicinal herbs purchased directly from the market. Therefore our estimate does not represent all consumption of AA herbs in Taiwan.

Conclusion
==========

This study showed a prescription profile of AA-CHPs in Taiwan between 1997 and 2003 based on the NHI reimbursement data, including an estimate of the total amount of AA herbs consumed and the target population requiring continuous monitoring. Moreover, this study revealed the NHI prescription of some banned AA-CHPs.
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